The Efficacy, Effectiveness, and Efficiency of Integrated QTc Assessment: Rationalizing Approaches to New Drug...

Area of Science:

• Pharmacology
• Drug Development
• Cardiovascular Safety

Background:

• Established regulatory paradigms exist for small molecule drugs regarding cardiac repolarization.
• Current guidance exempts large proteins and monoclonal antibodies from quantitative QTc assessments.
• The emergence of diverse new drug modalities necessitates a re-evaluation of risk assessment strategies.

Purpose of the Study:

• To address the regulatory uncertainty surrounding the cardiac safety assessment of novel drug modalities.
• To determine the appropriate risk assessment framework for new therapeutic classes beyond small molecules and monoclonal antibodies.

Main Methods:

• Review of existing regulatory guidance on drug-induced QT prolongation.
• Analysis of the characteristics of emerging drug modalities in relation to small molecules and large proteins.

Main Results:

• An integrated risk assessment paradigm is established for small molecule drugs.
• Regulatory guidance currently does not mandate quantitative QTc assessment for large proteins and monoclonal antibodies.

Conclusions:

• The expansion of new drug modalities presents a challenge to current regulatory frameworks.
• Further evaluation is needed to determine if new drug modalities should be assessed using small molecule or monoclonal antibody paradigms for cardiac safety.